AOD-9604 Peptide: What Is It Studied For?

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), spanning amino acids 177–191, with an additional tyrosine residue added at the N-terminus. A 2002 in vitro and rodent study confirmed that this tyrosine substitution distinguishes it from the unmodified hGH fragment 176–191 — the two are structurally related but not interchangeable, and literature on the unmodified fragment does not transfer to AOD-9604. The compound was originally designed to isolate the lipolytic properties of hGH while avoiding the diabetogenic effects associated with full-length growth hormone. It has been investigated primarily in obesity, lipid metabolism, and osteoarthritis research.

---

What Is AOD-9604 Studied For?

Research on AOD-9604 goes back to 2001 — nearly 30 years — with studies continuing through 2016.

1. Fat Metabolism and Weight Reduction — A 2001 preclinical study in obese (ob/ob) and lean C57BL/6J mice reported that chronic oral administration of AOD-9604 increased fat oxidation rates and reduced body weight, while in vitro assays indicated these effects were not mediated through the hGH receptor (Heffernan et al., International Journal of Obesity, PMID 11673763).

2. Beta-Adrenergic Pathway Involvement in Lipolysis — A separate 2001 mouse study, including beta(3)-adrenergic receptor knock-out animals, found that AOD-9604 retained partial lipolytic activity even in the absence of beta(3)-AR, suggesting additional receptor pathways contribute to its effects (Heffernan et al., Endocrinology, PMID 11713213).

3. Oral Bioavailability and Metabolic Activity in Obese Rodents — A 2001 preclinical study in obese Zucker rats reported that daily oral dosing for 19 days reduced body weight gain by more than 50% compared to untreated controls, alongside measurable changes in adipose tissue (Ng et al., Hormone Research, PMID 11146367).

4. Osteoarthritis Cartilage Protection — A 2016 rabbit preclinical study (n=32) evaluated intra-articular injection of AOD-9604 with or without hyaluronic acid in a collagenase-induced knee osteoarthritis model, examining structural outcomes in joint tissue (Kwon and Park, Annals of Clinical and Laboratory Science, PMID 26275694).

5. Human Clinical Trial Progression (Obesity) — Multiple Gateways to Clinical Trials entries in Methods and Findings in Experimental and Clinical Pharmacology (2004–2005) documented AOD-9604 advancing through phase II and phase III clinical evaluation for obesity; those entries, however, describe trial registration and progression rather than efficacy outcomes, and the human trial results — as detailed in the human research section below — were largely unimpressive. The human evidence here clusters around a small number of research groups, as noted below.

---

How Does AOD-9604 Work?

AOD-9604 acts on lipid metabolism through mechanisms that appear independent of the full hGH receptor. The 2001 in vitro work by Heffernan et al. (PMID 11673763) showed the compound did not stimulate cell proliferation via the hGH receptor, distinguishing its mechanism from growth hormone itself. The beta(3)-adrenergic receptor knock-out mouse study (PMID 11713213) demonstrated that lipolytic activity persisted even without functional beta(3)-AR signaling, pointing to at least one additional, unidentified pathway.

In obese Zucker rats, Ng et al. (PMID 11146367) observed that oral AOD-9604 administration produced changes in adipose tissue composition alongside reductions in weight gain, consistent with enhanced fat oxidation rather than lean mass reduction. The compound does not appear to stimulate insulin-like growth factor-1 (IGF-1) at the concentrations studied in these rodent models, which was part of the original rationale for its development as a weight-loss candidate without the metabolic side effects of full-length hGH.

---

What Does Animal Research Show?

Three primary rodent studies form the backbone of AOD-9604's preclinical evidence base. Two were published in 2001 by Heffernan and colleagues, and one by Ng and colleagues, also in 2001 — all using obese mouse or rat models.

The ob/ob mouse study (PMID 11673763) compared AOD-9604 against hGH and untreated controls over a chronic treatment period. Both compounds reduced body weight and increased fat oxidation in obese animals, while effects in lean mice were markedly smaller. The in vitro component confirmed the mechanism diverges from classical hGH receptor signaling.

The beta(3)-AR knock-out study (PMID 11713213) used a more targeted design to probe which adrenergic receptors mediate the lipolytic response. The finding that AOD-9604 retained activity in knock-out animals suggests the compound engages multiple receptor subtypes, though the precise pharmacology remains incompletely characterized in the published literature.

The obese Zucker rat study (PMID 11146367) added evidence for oral bioavailability — a practically significant finding, as many peptides are degraded before reaching systemic circulation. A 19-day oral dosing regimen produced a greater-than-50% reduction in body weight gain relative to controls, with histological changes in adipose tissue reported.

The 2016 rabbit osteoarthritis study (PMID 26275694, n=32) represents the only non-metabolic animal research in the pool. Using a collagenase-induced knee OA model, Kwon and Park evaluated intra-articular injection of AOD-9604 alone and in combination with hyaluronic acid. This study extended the research context beyond fat metabolism, though direct comparison to the earlier rodent obesity work is limited by the different model, species, and route of administration.

Across all animal studies, sample sizes are not reported in full detail for the mouse and rat experiments, which limits statistical precision assessment. Results are confined to obese or surgically induced disease models and should not be generalized to other conditions.

---

What Does Human Research Show?

Human research on AOD-9604 was documented primarily through clinical trial registry summaries published in Methods and Findings in Experimental and Clinical Pharmacology between 2004 and 2005 (PMIDs 14685303, 14571286, 15834452). These entries — from the Gateways to Clinical Trials series — recorded the compound's entry into phase II and phase III development for obesity treatment. The human data in this pool clusters around a small number of research groups: author Ng F M appears in three of the eight primary studies, and the Gateways series (authored by Bayés M and Prous J R) accounts for three additional entries.

Critically, the Gateways summaries describe trial status and registration rather than reporting outcome data. They confirm that human trials were conducted and reached late-phase development, but the published pool does not contain a full trial report with efficacy endpoints, primary outcome results, or adverse event tables. The absence of a positive phase III efficacy readout in the literature — combined with AOD-9604's absence from approved drug lists — is itself informative: the compound did not achieve regulatory approval for obesity despite advancing through late-phase trials.

A separate human-relevant study (PMID 25208511, Cox et al., Drug Testing and Analysis, 2015) examined detection and in vitro metabolism of AOD-9604, motivated by its status as a World Anti-Doping Agency (WADA)-banned substance. That study characterized metabolic pathways and urinary detection windows rather than therapeutic outcomes. Its classification as a WADA-prohibited substance reflects concern about potential use as a performance-enhancing drug, not an established performance benefit.

In aggregate, the human evidence does not demonstrate efficacy for any indication. The clinical trial record shows the compound was tested in humans at scale, but the results were insufficient to support approval, and detailed outcome data from those trials is not represented in the available study pool.

---

What Is Still Unknown About AOD-9604?

Several gaps limit interpretation of the existing evidence. The mechanism by which AOD-9604 exerts lipolytic effects — beyond ruling out classical hGH receptor signaling and partially ruling out beta(3)-AR dependence — remains uncharacterized at the receptor level. No published study in the pool identifies the specific binding target responsible for its activity in rodent adipose tissue.

The osteoarthritis rabbit study (PMID 26275694) opens a separate research question about joint tissue effects, but a single preclinical study in a collagenase-induced model provides limited basis for understanding whether any joint-protective mechanism generalizes beyond that model. No human OA data exists in the study pool.

The WADA detection study (PMID 25208511) establishes that AOD-9604 is metabolized and detectable in urine but does not characterize long-term metabolic fate or potential accumulation. Human pharmacokinetic data beyond detection windows is absent from the available literature.

The failure of phase III obesity trials to yield a published positive efficacy outcome leaves the translation gap between robust rodent fat-loss data and human response unresolved. Whether that gap reflects species differences in receptor expression, dosing challenges in humans, or study design factors is not answered by the current evidence pool.

---

Where Can I Buy AOD-9604?

AOD-9604 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---